November 14, 2014
1 min read
Save

FDA approves Pleximmune to predict risk for transplant rejection

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA recently approved a blood test used in predicting risk for transplant rejection in patients aged younger than 21 years who undergo liver or small bowel transplantation.

Using a small blood sample from the transplant patient, Pleximmune (Plexision) combines lymphocytes from the donor and recipient to stimulate a response in the recipient’s T-cytotoxic memory (TcM) cells. Pleximmune then measures the number of TcM cells from the transplant recipient that produce CD154 against nondonor human TcM cells. The final numeric score, or Immunoreactivity Index, indicates an increased or decreased risk for transplant rejection.

The test is intended for use in combination with other clinical information when managing anti-rejection therapy among patients with liver or small bowel transplants aged younger than 21 years.

There are no contraindications for Pleximmune, according to the FDA.